

29 April 2026

Dr Danielle Meyrick appointed as CEO to drive Stabl-Im clinical and commercial development

- **Dr Meyrick has over 20 years' experience across clinical development, radiopharmaceuticals and isotope-based technologies**
- **She has a proven track record in senior leadership roles at Telix Pharmaceuticals (ASX: TLX), ITM Isotopes and GenesisCare, directly supporting near term progression of Stabl-Im**
- **TRI's Stabl-Im platform has the potential to safely image and monitor brain cancers through standard MRI using stable isotope labelling of replicating cells within the brain**
- **Stabl-Im offers a potential breakthrough in the safe and non-invasive imaging of brain cancers**
- **Dr Meyrick's deep expertise in clinical trial design, execution and regulatory engagement to underpin near term progression of Stabl-Im technology**
- **Advanced negotiations with CROs underway with first clinical trials to commence shortly and complete this calendar year**

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to announce the appointment of Dr Danielle Meyrick (PhD, MD) as Chief Executive Officer, effective 1 June 2026.

Dr Meyrick is a highly experienced medical doctor, radiopharmaceutical chemist and biotechnology executive with over 20 years' international experience across drug development, clinical medicine, radiotheranostics and translational research. She brings deep expertise spanning the full development lifecycle, from preclinical development through to global Phase III trials and commercialisation, with a particular focus on oncology, nuclear medicine and isotope-based technologies.

Throughout her career, Dr Meyrick has held a number of senior leadership roles in the biotechnology and healthcare sectors, including Chief Medical Officer at ITM Isotopes Technologies Munich, Chief Medical Officer (APAC) and Global Head of Clinical Science at Telix Pharmaceuticals (ASX: TLX), and Chief Scientific Officer at GenesisCare. In these roles, she has led clinical development strategy, regulatory engagement (including FDA, EMA and TGA interactions), asset due diligence and program execution across advanced therapeutic and imaging platforms.

Her experience includes direct oversight of radiopharmaceutical and isotope-based programs, with responsibility for clinical trial design, execution and regulatory advancement, as well as leadership of imaging-based clinical programs and establishment of imaging core lab capabilities. Dr Meyrick has also served as a Principal and Sub-Investigator across multiple clinical trials, including Phase III studies, providing hands-on experience in trial delivery and patient-focused clinical research.

Dr Meyrick is currently Co-Founder and Managing Director of EPIC Theranostics, where she supports early-stage biotechnology companies in fundraising, clinical strategy and translational development. She also holds a number of Board and advisory roles across oncology and radiopharmaceutical organisations, further demonstrating strong industry networks and governance experience.

Dr Meyrick holds a Doctor of Medicine (MD) from the University of Western Australia and a PhD in Radiochemistry, alongside a Bachelor of Science (Honours) in Chemistry. She is AHPRA registered, GCP certified and a licensed radioisotope practitioner.

ASX ANNOUNCEMENT



Dr Meyrick's unique combination of isotope expertise, clinical development leadership and commercial experience positions her exceptionally well to advance TrivarX's Stabl-Im platform through near-term clinical studies and broader commercialisation initiatives.

In parallel to Dr Meyrick's appointment, the Company is advancing preparations for its first in-human clinical studies associated with Stabl-Im. TrivarX is currently in advanced negotiations with a number of leading Contract Research Organisations (CRO) to support trial design, site activation and program execution, alongside continued collaboration on clinical trial design with Stabl-Im inventor and founder, Dr Daniel Tillett. TrivarX remains well funded and on schedule to complete the proposed Phase 1 study this year.

Management commentary:

Incoming CEO, Dr Danielle Meyrick said: *"I'm excited to be joining TrivarX at such a pivotal stage in the development of the Stabl-Im platform. The combination of stable isotope science with MRI represents a highly differentiated and innovative approach, with the potential to redefine how we image and monitor disease, particularly in areas such as brain cancer where current options are limited."*

"Importantly, Stabl-Im has the potential to deliver a safe, non-invasive method to visualise cellular activity in real time, which could significantly improve how clinicians detect, monitor and manage disease progression. Ultimately, this has the potential to drive better outcomes for patients by enabling earlier intervention, more informed treatment decisions and improved care."

"In the near term, my focus will be on advancing the platform through clinical development, including first-in-human studies, while establishing a clear pathway toward regulatory approval and commercialisation. I look forward to working with the Board and team to realise the full potential of this technology."

Non-Executive Chairman, Mr David Trimboli said: *"Danielle's appointment represents a significant step forward for TrivarX as the Company continues to transition toward clinical development and commercialisation of the Stabl-Im platform. Her deep expertise in radiopharmaceuticals, isotope science and clinical trial execution is highly aligned with our near-term requirements to advance this technology."*

"Importantly, Danielle has demonstrated experience in translating complex scientific platforms into clinically and commercially viable programs, including engagement with global regulators, investors and strategic partners. This capability will be critical as we advance Stabl-Im as a safe imaging and monitoring platform for brain cancers."

A summary of the key terms of the employment agreement is set out in the attachment to this announcement.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About TrivarX Limited:

TrivarX Limited (ASX: TRI) is a healthcare technology company focused on developing innovative diagnostic and imaging solutions across mental health and neuro-oncology. The Company's proprietary

TrivarX Limited (A.B.N. 58 008 130 336)
647 Beaufort Street, Mount Lawley, WA 6050

ASX ANNOUNCEMENT



technologies include AI-driven algorithms for the detection of mental health conditions using physiological signals, and its Stabl-Im platform, which utilises stable isotope labelling combined with MRI to enable non-invasive imaging of cellular proliferation. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

Summary of key terms of Executive Service Agreement for Dr Danielle Meyrick

Key terms	Details		
Position	Chief Executive Officer		
Commencement Date	1 June 2026		
Term	The appointment of the CEO continues until terminated in accordance with the employment agreement (see below under Termination)		
Fixed Remuneration	\$300,000 per annum (exclusive of superannuation)		
Short-term incentive (FY26/27)	For the FY26/27 period, the Executive is entitled to earn up to 50% of Base Salary (to be awarded 40% in cash and 60% in Shares), subject to the achievement of the following Performance Targets: - Completion of a Phase 1 safety study of Stabl-Im as a brain tumour imaging agent in at least 20 subjects. (50% weight) - Preparation and submission of a pre-IND package to the FDA for Stabl-Im as a brain tumour imaging agent. (25% weight) - Completion of in vivo animal efficacy studies in at least one validated preclinical model of brain tumours, supporting the use of Stabl-Im beyond its use as a brain tumour imaging agent. (25% weight)		
Long-term incentives	Dr Meyrick will be offered 15,000,000 options with the following key terms:		
	No. of Options	Exercise Price	Option Vesting Condition
	5,000,000	A\$0.05	12 months of continuous service to the Company
	10,000,000	A\$0.10	12 months of continuous service to the Company
	Dr Meyrick will be offered 25,000,000 performance rights with the following key terms:		
	No. of Performance Rights	Performance Vesting Condition	Performance Period
	5,000,000	FDA allowance of an Investigational New Drug Application (IND) for Stabl-Im as a brain tumour imaging agent	On the date that is two (2) years after the PR Grant Date
5,000,000	Completion of a Phase 2 imaging study in at least 50 subjects with brain tumours, conducted under either an FDA-allowed IND or an Australian CTN submitted to the TGA, provided such completion occurs within 3.5 years from the date of issue.	On the date that is three (3) years and six (6) months after the PR Grant Date	
5,000,000	FDA allowance of an Investigational New Drug Application (IND) for Stabl-Im beyond its use as a brain tumour imaging agent	On the date that is three (3) years after the PR Grant Date	

ASX ANNOUNCEMENT



	10,000,000	Completion of a Phase 1 trial in at least 30 subjects with brain tumours for any indication beyond imaging OR FDA Fast Track/Breakthrough or Orphan designation for broader indication	On the date that is five (5) years after the PR Grant Date
Future STI/LTI	The Executive will be eligible to participate in the Employee Incentive Plan. Any future opportunities to participate in short-term incentives may be offered to the Executive on terms and conditions determined by the Board.		
Termination/cessation of employment	The Company or Executive may terminate by giving the Executive six (6) months' written notice. There are provisions for termination without notice in certain circumstances.		